134 related articles for article (PubMed ID: 38395299)
1. Validation of the SCORE2 risk prediction algorithm in a Portuguese population: A new model to estimate 10-year cardiovascular disease incidence in Europe.
Temtem M; Mendonça MI; Santos M; Sá D; Sousa F; Freitas S; Borges S; Henriques E; Rodrigues M; Soares C; Rodrigues R; Serrão M; Drumond A; Sousa AC; Palma Reis R
Rev Port Cardiol; 2024 Feb; ():. PubMed ID: 38395299
[TBL] [Abstract][Full Text] [Related]
2. Predictive improvement of adding coronary calcium score and a genetic risk score to a traditional risk model for cardiovascular event prediction.
Temtem M; Mendonça MI; Gomes Serrão M; Santos M; Sá D; Sousa F; Soares C; Rodrigues R; Henriques E; Freitas S; Borges S; Rodrigues M; Guerra G; Drumond Freitas A; Sousa AC; Palma Dos Reis R
Eur J Prev Cardiol; 2024 Apr; 31(6):709-715. PubMed ID: 38175668
[TBL] [Abstract][Full Text] [Related]
3. Validation of the general Framingham Risk Score (FRS), SCORE2, revised PCE and WHO CVD risk scores in an Asian population.
Kasim SS; Ibrahim N; Malek S; Ibrahim KS; Aziz MF; Song C; Chia YC; Ramli AS; Negishi K; Mat Nasir N
Lancet Reg Health West Pac; 2023 Jun; 35():100742. PubMed ID: 37424687
[TBL] [Abstract][Full Text] [Related]
4. Validation of Systematic Coronary Risk Evaluation 2 (SCORE2) and SCORE2-Older Persons in the EPIC-Norfolk prospective population cohort.
van Trier TJ; Snaterse M; Boekholdt SM; Scholte Op Reimer WJM; Hageman SHJ; Visseren FLJ; Dorresteijn JAN; Peters RJG; Jørstad HT
Eur J Prev Cardiol; 2024 Jan; 31(2):182-189. PubMed ID: 37793098
[TBL] [Abstract][Full Text] [Related]
5. SCORE2 Assessment in the Calculation of Cardiovascular Risk in Patients with Rheumatoid Arthritis.
Ferraz-Amaro I; Corrales A; Atienza-Mateo B; Vegas-Revenga N; Prieto-Peña D; Sánchez-Martín J; Almeida C; Quevedo-Abeledo JC; Blanco R; González-Gay MÁ
Diagnostics (Basel); 2021 Dec; 11(12):. PubMed ID: 34943599
[TBL] [Abstract][Full Text] [Related]
6. Improving 10-year cardiovascular risk prediction in apparently healthy people: flexible addition of risk modifiers on top of SCORE2.
Hageman SHJ; Petitjaen C; Pennells L; Kaptoge S; Pajouheshnia R; Tillmann T; Blaha MJ; McClelland RL; Matsushita K; Nambi V; Klungel OH; Souverein PC; van der Schouw YT; Verschuren WMM; Lehmann N; Erbel R; Jöckel KH; Di Angelantonio E; Visseren FLJ; Dorresteijn JAN
Eur J Prev Cardiol; 2023 Oct; 30(15):1705-1714. PubMed ID: 37264679
[TBL] [Abstract][Full Text] [Related]
7. SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe.
SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration
Eur Heart J; 2023 Jul; 44(28):2544-2556. PubMed ID: 37247330
[TBL] [Abstract][Full Text] [Related]
8. New Way to "SCORE" Risk: Updates on the ESC Scoring System and Incorporation into ESC Cardiovascular Prevention Guidelines.
Graham IM; Di Angelantonio E; Huculeci R;
Curr Cardiol Rep; 2022 Nov; 24(11):1679-1684. PubMed ID: 36441402
[TBL] [Abstract][Full Text] [Related]
9. Statin Eligibility for Primary Prevention of Cardiovascular Disease According to 2021 European Prevention Guidelines Compared With Other International Guidelines.
Mortensen MB; Tybjærg-Hansen A; Nordestgaard BG
JAMA Cardiol; 2022 Aug; 7(8):836-843. PubMed ID: 35793078
[TBL] [Abstract][Full Text] [Related]
10. SCORE2
Quevedo-Abeledo JC; González-Gay MÁ; Ferraz-Amaro I
Ther Adv Musculoskelet Dis; 2022; 14():1759720X221092373. PubMed ID: 35464811
[TBL] [Abstract][Full Text] [Related]
11. SCORE2 Screening Tool for Cardiovascular Risk Assessment in Psoriasis-A Case-Control Study.
Kampe T; Baloghová J; Kolarčik P; Rimárová K; Dorko E
J Clin Med; 2024 May; 13(11):. PubMed ID: 38892947
[No Abstract] [Full Text] [Related]
12. Cardiovascular risk assessment in Portugal's primary health care system: SCORE vs. SCORE2.
Silva C; Mendes JE; Ramos R; Gaspar A; Leal F; Mendes N
Rev Port Cardiol; 2024 Feb; ():. PubMed ID: 38395300
[TBL] [Abstract][Full Text] [Related]
13. Performance of SCORE2 and SCORE2-OP risk algorithms in a Cypriot cohort.
Nicolaides AN; Griffin M; Panayiotou AG; Tyllis T; Bond D; Georgiou N; Kyriacou E; Avraamides C; Martin RM
Int Angiol; 2022 Dec; 41(6):492-499. PubMed ID: 36285529
[TBL] [Abstract][Full Text] [Related]
14. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe.
SCORE2 working group and ESC Cardiovascular risk collaboration
Eur Heart J; 2021 Jul; 42(25):2439-2454. PubMed ID: 34120177
[TBL] [Abstract][Full Text] [Related]
15. SCORE2 cardiovascular risk prediction models in an ethnic and socioeconomic diverse population in the Netherlands: an external validation study.
Kist JM; Vos RC; Mairuhu ATA; Struijs JN; van Peet PG; Vos HMM; van Os HJA; Beishuizen ED; Sijpkens YWJ; Faiq MA; Numans ME; Groenwold RHH
EClinicalMedicine; 2023 Mar; 57():101862. PubMed ID: 36864978
[TBL] [Abstract][Full Text] [Related]
16. Eligibility for lipid-lowering therapy when applying systemic coronary risk estimation 2 (SCORE2) according to guidelines on apparently healthy middle-aged individuals.
Yari A; Ueda P; Lundman P; Alfredsson J; Ravn-Fischer A; Söderberg S; Yndigegn T; Hagström E; Jernberg T
Eur J Prev Cardiol; 2024 Jun; ():. PubMed ID: 38842486
[TBL] [Abstract][Full Text] [Related]
17. Including measures of chronic kidney disease to improve cardiovascular risk prediction by SCORE2 and SCORE2-OP.
Matsushita K; Kaptoge S; Hageman SHJ; Sang Y; Ballew SH; Grams ME; Surapaneni A; Sun L; Arnlov J; Bozic M; Brenner H; Brunskill NJ; Chang AR; Chinnadurai R; Cirillo M; Correa A; Ebert N; Eckardt KU; Gansevoort RT; Gutierrez O; Hadaegh F; He J; Hwang SJ; Jafar TH; Jassal SK; Kayama T; Kovesdy CP; Landman GW; Levey AS; Lloyd-Jones DM; Major RW; Miura K; Muntner P; Nadkarni GN; Nowak C; Ohkubo T; Pena MJ; Polkinghorne KR; Sairenchi T; Schaeffner E; Schneider MP; Shalev V; Shlipak MG; Solbu MD; Stempniewicz N; Tollitt J; Valdivielso JM; van der Leeuw J; Wang AY; Wen CP; Woodward M; Yamagishi K; Yatsuya H; Zhang L; Dorresteijn JAN; Di Angelantonio E; Visseren FLJ; Pennells L; Coresh J
Eur J Prev Cardiol; 2023 Jan; 30(1):8-16. PubMed ID: 35972749
[TBL] [Abstract][Full Text] [Related]
18. Validation of SCORE2 on a sample from the Russian population and adaptation for the very high cardiovascular disease risk region.
Svinin GE; Kutsenko VA; Shalnova SA; Yarovaya EB; Imaeva AE; Balanova YA; Kapustina AV; Muromtseva GA; Drapkina OM
PLoS One; 2024; 19(4):e0300974. PubMed ID: 38630773
[TBL] [Abstract][Full Text] [Related]
19. Utility of SCORE2 risk algorithm for predicting life course accelerated frailty and physical function decline.
Li C; Ma Y; Hua R; Zheng F; Xie W
J Cachexia Sarcopenia Muscle; 2023 Feb; 14(1):596-605. PubMed ID: 36572545
[TBL] [Abstract][Full Text] [Related]
20. Combining European and U.S. risk prediction models with polygenic risk scores to refine cardiovascular prevention: the CoLaus|PsyCoLaus Study.
de La Harpe R; Thorball CW; Redin C; Fournier S; Müller O; Strambo D; Michel P; Vollenweider P; Marques-Vidal P; Fellay J; Vaucher J
Eur J Prev Cardiol; 2023 May; 30(7):561-571. PubMed ID: 36652418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
